Free Trial
→ What to do with your collapsing portfolio… (From Brownstone Research) (Ad) Buy RPRX Stock  Free RPRX Stock Alerts

Royalty Pharma (RPRX) Financials

Royalty Pharma logo
$32.45 +0.16 (+0.50%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$32.46 +0.00 (+0.02%)
As of 04/15/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Royalty Pharma

Annual Income Statements for Royalty Pharma

This table shows Royalty Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 1,378 2,349 975 620 43 1,135 859
Consolidated Net Income / (Loss)		 1,518 2,461 1,702 1,241 230 1,700 1,331
Net Income / (Loss) Continuing Operations		 1,518 2,461 1,702 1,241 230 1,700 1,331
Total Pre-Tax Income 		1,518 2,461 1,702 1,241 230 1,700 1,331
Total Operating Income		 1,364 2,623 1,595 1,431 307 1,492 1,292
Total Gross Profit		 1,795 1,814 2,122 2,289 2,237 2,355 2,264
Total Revenue		 1,795 1,814 2,122 2,289 2,237 2,355 2,264
Operating Revenue		 1,795 1,814 2,122 2,289 2,237 2,355 2,264
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 430 -809 527 859 1,930 862 971
Selling, General & Admin Expense		 62 103 182 183 227 250 237
Research & Development Expense		 393 83 26 200 177 52 2.00
Amortization Expense		 33 24 23 23 5.67 0.00 0.00
Other Operating Expenses / (Income)		 -57 -1,019 231 453 904 561 732
Impairment Charge		 - - 65 0.00 616 0.00 0.00
Total Other Income / (Expense), net		 153 -162 107 -190 -77 208 38
Interest Expense		 280 269 157 166 188 187 226
Interest & Investment Income		 17 -10 73 34 69 101 77
Other Income / (Expense), net		 416 117 191 -57 42 294 187
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 140 113 727 621 187 565 472
Basic Earnings per Share		 $0.00 $0.00 $1.32 $1.49 $0.10 $2.54 $1.92
Weighted Average Basic Shares Outstanding		 0.00 0.00 375.44M 414.79M 437.96M 447.60M 448.19M
Diluted Earnings per Share		 $0.00 $0.00 $1.32 $1.49 $0.10 $2.53 $1.91
Weighted Average Diluted Shares Outstanding		 0.00 0.00 375.46M 414.80M 437.97M 602.90M 594.11M
Weighted Average Basic & Diluted Shares Outstanding		 - - 607.11M 607.18M 607.22M 597.43M 576.45M
Cash Dividends to Common per Share		 - - $0.15 $0.68 $0.76 $0.80 $0.84

Quarterly Income Statements for Royalty Pharma

This table shows Royalty Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 143 -456 341 228 72 494 4.78 102 544 208
Consolidated Net Income / (Loss)		 220 -610 509 351 122 718 -4.27 194 806 334
Net Income / (Loss) Continuing Operations		 220 -610 509 351 122 718 -4.27 194 806 334
Total Pre-Tax Income 		220 -610 509 351 122 718 -4.27 194 806 334
Total Operating Income		 192 -483 479 249 151 613 -74 270 735 362
Total Gross Profit		 573 566 684 538 536 596 568 537 565 594
Total Revenue		 573 566 684 538 536 596 568 537 565 594
Operating Revenue		 573 566 684 538 536 596 568 537 565 594
Total Operating Expenses		 381 1,048 205 289 385 -17 642 268 -170 232
Selling, General & Admin Expense		 51 73 86 48 57 59 58 55 57 68
Research & Development Expense		 26 51 0.50 0.50 51 0.50 0.50 0.50 0.50 0.50
Other Operating Expenses / (Income)		 305 309 119 241 277 -77 584 212 -228 164
Total Other Income / (Expense), net		 28 -127 30 102 -29 105 70 -75 71 -27
Interest Expense		 47 47 47 47 46 47 44 49 67 66
Interest & Investment Income		 11 37 51 25 18 6.77 -6.73 15 28 41
Other Income / (Expense), net		 64 -117 26 125 -1.55 145 120 -41 110 -2.09
Net Income / (Loss) Attributable to Noncontrolling Interest		 78 -154 168 124 50 223 -9.05 92 262 126
Basic Earnings per Share		 $0.32 ($1.04) $0.76 $0.51 $0.16 $1.11 $0.01 $0.23 $1.22 $0.46
Weighted Average Basic Shares Outstanding		 439.29M 437.96M 445.61M 450.41M 448.44M 447.60M 448.62M 451.02M 447.63M 448.19M
Diluted Earnings per Share		 $0.32 ($1.04) $0.76 $0.50 $0.16 $1.11 $0.01 $0.23 $1.21 $0.46
Weighted Average Diluted Shares Outstanding		 607.23M 437.97M 607.25M 605.86M 601.14M 602.90M 597.48M 596.91M 592.73M 594.11M
Weighted Average Basic & Diluted Shares Outstanding		 607.22M 607.22M 607.14M 601.82M 597.43M 597.43M 597.44M 593.46M 589.18M 576.45M

Annual Cash Flow Statements for Royalty Pharma

This table details how cash moves in and out of Royalty Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 543 -1,678 762 532 170 -1,234 452
Net Cash From Operating Activities		 1,618 1,667 2,035 2,018 2,144 2,988 2,769
Net Cash From Continuing Operating Activities		 1,618 1,647 2,027 2,014 2,144 2,988 2,769
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 1,615 1,647 2,035 2,014 2,144 2,988 2,769
Net Cash From Investing Activities		 303 -2,154 -2,759 -1,870 -1,029 -2,073 -2,678
Net Cash From Continuing Investing Activities		 303 -2,154 -2,759 -1,870 -1,029 -2,073 -2,678
Acquisitions		 -24 -27 -40 -35 -9.90 -13 -11
Purchase of Investments		 -422 -2,743 -3,938 -3,594 -2,565 -2,116 -2,736
Sale and/or Maturity of Investments		 750 875 834 1,777 1,334 70 43
Other Investing Activities, net		 0.00 -259 385 -19 211 -14 26
Net Cash From Financing Activities		 -1,379 -1,192 1,487 385 -945 -2,149 361
Net Cash From Continuing Financing Activities		 -1,379 -1,192 1,487 385 -945 -2,154 361
Repayment of Debt		 -296 -294 -11,257 -13 -1.35 -1,352 -22
Repurchase of Common Equity		 0.00 -4.27 - 0.00 0.00 -305 -230
Payment of Dividends		 -1,083 -893 -1,123 -919 -951 -855 -864
Issuance of Debt		 0.00 0.00 11,891 1,273 0.00 350 1,471
Other Financing Activities, net		 0.00 0.00 67 44 7.19 7.48 5.11

Quarterly Cash Flow Statements for Royalty Pharma

This table details how cash moves in and out of Royalty Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -1,116 719 265 197 -1,237 -459 366 922 -815 -21
Net Cash From Operating Activities		 539 570 1,034 608 574 773 665 658 704 743
Net Cash From Continuing Operating Activities		 532 580 1,034 608 574 773 658 665 704 743
Non-Cash Adjustments To Reconcile Net Income		 532 580 1,034 608 574 773 658 665 704 743
Net Cash From Investing Activities		 -1,425 415 -559 -63 -451 -1,000 -87 -893 -1,193 -506
Net Cash From Continuing Investing Activities		 -1,425 415 -559 -63 -451 -1,000 -87 -893 -1,193 -506
Purchase of Investments		 -1,631 -361 -602 -60 -451 -1,002 -86 -947 -1,207 -496
Sale and/or Maturity of Investments		 213 565 59 - 4.46 6.10 6.41 6.82 113 -83
Other Investing Activities, net		 - 211 -12 - - -2.04 0.00 51 -99 74
Net Cash From Financing Activities		 -230 -266 -210 -347 -1,359 -232 -212 1,157 -326 -258
Net Cash From Continuing Financing Activities		 -230 -266 -210 -163 -1,259 -522 -212 1,336 -224 -539
Repayment of Debt		 - -1.35 - - -1,000 -352 - - -3.09 -0.30
Repurchase of Common Equity		 - - - - -140 -30 - - -97 -53
Payment of Dividends		 -232 -266 -214 -29 -121 -491 -213 -38 -125 -487
Other Financing Activities, net		 1.86 1.35 3.59 1.03 1.75 1.11 1.43 1.17 1.26 1.25

Annual Balance Sheets for Royalty Pharma

This table presents Royalty Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 12,450 16,020 17,516 16,813 16,382 18,223
Total Current Assets		 832 2,697 2,878 2,555 1,274 1,802
Cash & Equivalents		 246 1,009 1,541 1,711 477 929
Short-Term Investments		 94 1,053 648 26 18 58
Note & Lease Receivable		 453 587 614 691 738 784
Other Current Assets		 39 48 75 127 40 31
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 11,618 13,323 14,638 14,259 15,108 16,421
Long-Term Investments		 255 618 640 623 813 1,073
Noncurrent Note & Lease Receivables		 10,842 12,368 13,718 13,493 14,089 15,127
Other Noncurrent Operating Assets		 469 309 274 142 206 220
Total Liabilities & Shareholders' Equity		 12,450 16,020 17,516 16,813 16,382 18,223
Total Liabilities		 6,308 6,124 7,267 7,288 6,298 7,880
Total Current Liabilities		 333 308 171 1,167 161 1,254
Short-Term Debt		 282 - 0.00 998 0.00 998
Accounts Payable		 42 137 114 7.91 15 13
Other Current Liabilities		 9.22 19 0.00 107 95 144
Other Current Nonoperating Liabilities		 0.00 42 58 54 52 98
Total Noncurrent Liabilities		 5,975 5,817 7,096 6,121 6,136 6,627
Long-Term Debt		 5,956 5,817 7,096 6,119 6,135 6,615
Other Noncurrent Operating Liabilities		 19 - 0.00 2.50 0.90 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6,141 9,896 10,249 9,525 10,084 10,342
Total Preferred & Common Equity		 2,823 4,819 5,777 5,628 6,526 6,947
Total Common Equity		 2,823 4,819 5,777 5,628 6,526 6,947
Common Stock		 0.00 2,866 3,508 3,666 4,012 4,104
Retained Earnings		 2,825 1,921 2,255 1,965 2,518 2,846
Treasury Stock		 -4.27 -2.32 -2.72 -2.81 -2.63 -2.66
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest		 3,318 5,077 4,472 3,897 3,558 3,396

Quarterly Balance Sheets for Royalty Pharma

This table presents Royalty Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 17,673 17,074 17,121 15,856 16,131 17,657 18,042
Total Current Assets		 2,342 2,631 2,954 1,729 1,560 2,579 1,794
Cash & Equivalents		 992 1,976 2,173 936 843 1,765 950
Short-Term Investments		 549 2.50 5.10 5.30 29 39 49
Note & Lease Receivable		 676 610 730 742 660 750 766
Other Current Assets		 125 43 45 45 27 26 30
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 15,330 14,443 14,168 14,127 14,571 15,077 16,248
Long-Term Investments		 750 652 728 732 824 982 1,008
Noncurrent Note & Lease Receivables		 14,287 13,662 13,268 13,230 13,465 13,890 14,968
Other Noncurrent Operating Assets		 293 130 172 165 282 206 272
Total Liabilities & Shareholders' Equity		 17,673 17,074 17,121 15,856 16,131 17,657 18,042
Total Liabilities		 7,256 7,252 7,308 6,270 6,267 7,905 7,784
Total Current Liabilities		 1,132 1,117 1,172 128 125 276 1,168
Short-Term Debt		 997 998 999 0.00 - - 997
Accounts Payable		 122 105 5.81 14 12 23 22
Other Current Liabilities		 - 0.00 113 102 100 196 110
Other Current Nonoperating Liabilities		 13 13 54 13 13 56 38
Total Noncurrent Liabilities		 6,125 6,135 6,136 6,142 6,143 7,629 6,616
Long-Term Debt		 6,115 6,123 6,127 6,131 6,139 7,602 6,610
Other Noncurrent Operating Liabilities		 9.90 12 8.50 11 3.22 27 5.58
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 10,416 9,822 9,814 9,585 9,864 9,752 10,258
Total Preferred & Common Equity		 6,152 5,954 6,282 6,139 6,500 6,476 6,870
Total Common Equity		 6,152 5,954 6,282 6,139 6,500 6,476 6,870
Common Stock		 3,633 3,740 4,031 4,007 4,075 4,101 4,108
Retained Earnings		 2,505 2,217 2,253 2,135 2,427 2,378 2,765
Treasury Stock		 -2.79 -2.83 -2.63 -2.62 -2.65 -2.66 -2.66
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest		 4,264 3,868 3,532 3,446 3,364 3,276 3,389

Annual Metrics and Ratios for Royalty Pharma

This table displays calculated financial ratios and metrics derived from Royalty Pharma's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 1.08% 16.98% 7.87% -2.28% 5.24% -3.86%
EBITDA Growth		 0.00% 52.40% -34.55% -22.82% -74.62% 404.07% -17.17%
EBIT Growth		 0.00% 53.91% -34.82% -23.12% -74.61% 412.27% -17.17%
NOPAT Growth		 0.00% 92.25% -39.18% -10.32% -78.54% 385.94% -13.38%
Net Income Growth		 0.00% 62.16% -30.85% -27.07% -81.46% 638.96% -21.72%
EPS Growth		 0.00% 0.00% 0.00% 12.88% -93.29% 2,430.00% -24.51%
Operating Cash Flow Growth		 0.00% 3.02% 22.04% -0.84% 6.27% 39.36% -7.32%
Free Cash Flow Firm Growth		 0.00% 0.00% 103.32% -122.42% 898.38% 58.81% -69.63%
Invested Capital Growth		 0.00% 0.00% 10.96% 11.46% -1.63% 4.37% 6.88%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.16% -0.44% 1.30% -0.11%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -14.91% -67.44% 317.36% -21.23%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -15.13% -67.62% 317.36% -21.23%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -10.09% -67.44% 276.24% -16.28%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -20.14% -74.26% 356.43% -22.36%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -23.20% -91.15% 565.79% -25.39%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 4.48% -3.62% 3.87% 7.28% -1.08%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 32.36% -45.65% 188.06%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -0.99% -6.00% 6.46% 0.60%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 101.05% 152.35% 85.25% 60.99% 15.84% 75.86% 65.36%
Operating Margin		 76.02% 144.59% 75.17% 62.49% 13.73% 63.37% 57.10%
EBIT Margin		 99.19% 151.04% 84.16% 59.98% 15.58% 75.86% 65.36%
Profit (Net Income) Margin		 84.57% 135.67% 80.19% 54.21% 10.28% 72.20% 58.79%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 85.25% 89.83% 95.28% 90.38% 65.98% 95.18% 89.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 44.52% 12.84% 10.35% 2.12% 10.19% 8.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 38.79% 15.25% 5.30% 0.44% 14.48% 9.08%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 35.64% 8.39% 1.97% 0.20% 7.15% 4.68%
Return on Equity (ROE)		 0.00% 80.16% 21.23% 12.32% 2.33% 17.34% 13.03%
Cash Return on Invested Capital (CROIC)		 0.00% -155.48% 2.45% -0.49% 3.77% 5.91% 1.70%
Operating Return on Assets (OROA)		 0.00% 22.01% 12.55% 8.19% 2.03% 10.76% 8.55%
Return on Assets (ROA)		 0.00% 19.77% 11.96% 7.40% 1.34% 10.24% 7.69%
Return on Common Equity (ROCE)		 0.00% 36.85% 10.11% 6.48% 1.34% 10.75% 8.59%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 87.19% 35.32% 21.49% 4.09% 26.05% 19.16%
Net Operating Profit after Tax (NOPAT)		 1,364 2,623 1,595 1,431 307 1,492 1,292
NOPAT Margin		 76.02% 144.59% 75.17% 62.49% 13.73% 63.37% 57.10%
Net Nonoperating Expense Percent (NNEP)		 0.00% 5.73% -2.42% 5.05% 1.69% -4.29% -0.73%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 1.85% 9.20% 7.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 3.45% 5.70% 8.56% 7.99% 10.16% 10.61% 10.46%
R&D to Revenue		 21.87% 4.58% 1.24% 8.74% 7.92% 2.21% 0.09%
Operating Expenses to Revenue		 23.98% -44.59% 24.83% 37.51% 86.27% 36.63% 42.90%
Earnings before Interest and Taxes (EBIT)		 1,780 2,740 1,786 1,373 349 1,786 1,479
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1,814 2,764 1,809 1,396 354 1,786 1,479
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.66 3.71 3.92 4.03 2.49 2.16
Price to Tangible Book Value (P/TBV)		 0.00 0.67 3.74 3.92 4.03 2.49 2.16
Price to Revenue (P/Rev)		 1.03 1.02 8.43 9.89 10.14 6.91 6.64
Price to Earnings (P/E)		 1.35 0.79 18.35 36.55 529.67 14.34 17.50
Dividend Yield		 0.00% 0.00% 0.65% 1.82% 2.03% 2.94% 3.29%
Earnings Yield		 74.27% 126.61% 5.45% 2.74% 0.19% 6.97% 5.72%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.92 2.00 2.15 2.19 1.65 1.50
Enterprise Value to Revenue (EV/Rev)		 0.00 5.96 12.30 13.71 14.01 10.47 10.59
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 3.91 14.43 22.48 88.45 13.81 16.21
Enterprise Value to EBIT (EV/EBIT)		 0.00 3.95 14.62 22.86 89.89 13.81 16.21
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 4.12 16.36 21.94 102.07 16.53 18.55
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 6.49 12.83 15.56 14.62 8.25 8.66
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 85.79 0.00 57.53 28.51 91.28
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 1.02 0.59 0.69 0.75 0.61 0.74
Long-Term Debt to Equity		 0.00 0.97 0.59 0.69 0.64 0.61 0.64
Financial Leverage		 0.00 0.92 0.55 0.37 0.46 0.49 0.52
Leverage Ratio		 0.00 2.03 1.78 1.66 1.74 1.69 1.69
Compound Leverage Factor		 0.00 1.82 1.69 1.50 1.15 1.61 1.52
Debt to Total Capital		 0.00% 50.39% 37.02% 40.91% 42.76% 37.83% 42.40%
Short-Term Debt to Total Capital		 0.00% 2.28% 0.00% 0.00% 5.99% 0.00% 5.56%
Long-Term Debt to Total Capital		 0.00% 48.11% 37.02% 40.91% 36.77% 37.83% 36.84%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 26.81% 32.31% 25.78% 23.42% 21.94% 18.91%
Common Equity to Total Capital		 0.00% 22.80% 30.67% 33.30% 33.82% 40.24% 38.69%
Debt to EBITDA		 0.00 2.26 3.21 5.08 20.08 3.44 5.15
Net Debt to EBITDA		 0.00 2.04 1.73 3.06 13.42 2.70 3.75
Long-Term Debt to EBITDA		 0.00 2.15 3.21 5.08 17.27 3.44 4.47
Debt to NOPAT		 0.00 2.38 3.65 4.96 23.18 4.11 5.89
Net Debt to NOPAT		 0.00 2.15 1.97 2.98 15.49 3.23 4.30
Long-Term Debt to NOPAT		 0.00 2.27 3.65 4.96 19.93 4.11 5.12
Altman Z-Score		 0.00 1.41 2.60 2.63 2.33 2.35 1.79
Noncontrolling Interest Sharing Ratio		 0.00% 54.03% 52.35% 47.40% 42.32% 38.02% 34.04%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 2.50 8.76 16.81 2.19 7.90 1.44
Quick Ratio		 0.00 2.38 8.60 16.37 2.08 7.65 1.41
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9,160 304 -68 545 865 263
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -34.11 1.94 -0.41 2.90 4.62 1.16
Operating Cash Flow to Interest Expense		 5.78 6.21 12.95 12.14 11.41 15.96 12.28
Operating Cash Flow Less CapEx to Interest Expense		 5.78 6.21 12.95 12.14 11.41 15.96 12.28
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.15 0.15 0.14 0.13 0.14 0.13
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 11,784 13,075 14,574 14,336 14,963 15,993
Invested Capital Turnover		 0.00 0.31 0.17 0.17 0.15 0.16 0.15
Increase / (Decrease) in Invested Capital		 0.00 11,784 1,291 1,499 -238 627 1,030
Enterprise Value (EV)		 0.00 10,816 26,108 31,389 31,341 24,661 23,978
Market Capitalization		 1,855 1,855 17,894 22,649 22,687 16,276 15,030
Book Value per Share		 $0.00 $40.33 $12.42 $9.51 $9.27 $10.92 $11.79
Tangible Book Value per Share		 $0.00 $39.59 $12.34 $9.50 $9.27 $10.92 $11.79
Total Capital		 0.00 12,380 15,712 17,345 16,642 16,220 17,955
Total Debt		 0.00 6,238 5,817 7,096 7,116 6,135 7,612
Total Long-Term Debt		 0.00 5,956 5,817 7,096 6,119 6,135 6,615
Net Debt		 0.00 5,642 3,137 4,267 4,756 4,827 5,552
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 440 327 518 649 618 559
Debt-free Net Working Capital (DFNWC)		 0.00 781 2,389 2,707 2,386 1,113 1,546
Net Working Capital (NWC)		 0.00 499 2,389 2,707 1,388 1,113 549
Net Nonoperating Expense (NNE)		 -153 162 -107 190 77 -208 -38
Net Nonoperating Obligations (NNO)		 0.00 5,642 3,179 4,325 4,811 4,879 5,650
Total Depreciation and Amortization (D&A)		 33 24 23 23 5.67 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 24.25% 15.41% 22.63% 29.02% 26.23% 24.70%
Debt-free Net Working Capital to Revenue		 0.00% 43.03% 112.56% 118.24% 106.63% 47.26% 68.31%
Net Working Capital to Revenue		 0.00% 27.49% 112.56% 118.24% 62.05% 47.26% 24.23%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.32 $1.49 $0.10 $2.54 $1.92
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 375.44M 414.79M 437.96M 447.60M 448.19M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $1.32 $1.49 $0.10 $2.53 $1.91
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 375.46M 414.80M 437.97M 602.90M 594.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 607.11M 607.18M 607.22M 597.43M 576.45M
Normalized Net Operating Profit after Tax (NOPAT)		 955 1,836 1,162 1,002 646 1,045 905
Normalized NOPAT Margin		 53.21% 101.21% 54.77% 43.74% 28.88% 44.36% 39.97%
Pre Tax Income Margin		 84.57% 135.67% 80.19% 54.21% 10.28% 72.20% 58.79%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 6.36 10.20 11.37 8.27 1.86 9.54 6.56
NOPAT to Interest Expense		 4.87 9.77 10.16 8.61 1.63 7.97 5.73
EBIT Less CapEx to Interest Expense		 6.36 10.20 11.37 8.27 1.86 9.54 6.56
NOPAT Less CapEx to Interest Expense		 4.87 9.77 10.16 8.61 1.63 7.97 5.73
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 71.35% 36.29% 65.98% 74.01% 413.23% 50.28% 64.92%
Augmented Payout Ratio		 71.35% 36.47% 65.98% 74.01% 413.23% 68.21% 82.17%

Quarterly Metrics and Ratios for Royalty Pharma

This table displays calculated financial ratios and metrics derived from Royalty Pharma's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -2.10% -1.73% 21.69% 0.42% -6.48% 5.36% -16.96% -0.17% 5.29% -0.41%
EBITDA Growth		 -0.12% -548.40% 195.35% -29.13% -41.59% 226.33% -90.75% -38.86% 463.69% -52.59%
EBIT Growth		 2.19% -568.70% 205.49% -29.13% -41.59% 226.33% -90.75% -38.86% 463.69% -52.59%
NOPAT Growth		 -36.58% -320.22% 117.99% -34.13% -21.21% 281.41% -110.78% 8.35% 385.38% -41.02%
Net Income Growth		 -0.62% -1,236.61% 297.47% -28.53% -44.61% 217.63% -100.84% -44.67% 560.53% -53.41%
EPS Growth		 33.33% -10,300.00% 533.33% -28.57% -50.00% 206.73% -98.68% -54.00% 656.25% -58.56%
Operating Cash Flow Growth		 14.70% 16.32% 124.62% 5.72% 6.44% 35.57% -35.71% 8.29% 22.68% -3.90%
Free Cash Flow Firm Growth		 78.46% 92.56% 148.75% 222.56% 496.77% 85.88% -110.83% -154.30% -182.22% -4,623.87%
Invested Capital Growth		 3.61% -1.63% 0.48% -1.70% -7.84% 4.37% -0.05% 3.81% 13.11% 6.88%
Revenue Q/Q Growth		 7.00% -1.35% 20.90% -21.31% -0.35% 11.14% -4.71% -5.41% 5.10% 5.13%
EBITDA Q/Q Growth		 -51.30% -333.85% 184.11% -26.02% -59.86% 405.73% -93.84% 388.97% 270.10% -57.46%
EBIT Q/Q Growth		 -51.30% -333.85% 184.11% -26.02% -59.86% 405.73% -93.84% 388.97% 270.10% -57.46%
NOPAT Q/Q Growth		 -49.12% -275.78% 241.77% -48.05% -39.14% 304.71% -108.43% 622.12% 172.62% -50.82%
Net Income Q/Q Growth		 -55.16% -376.77% 183.45% -30.99% -65.25% 487.81% -100.60% 4,648.96% 314.84% -58.54%
EPS Q/Q Growth		 -54.29% -425.00% 173.08% -34.21% -68.00% 593.75% -99.10% 2,200.00% 426.09% -61.98%
Operating Cash Flow Q/Q Growth		 -6.28% 5.77% 81.40% -41.21% -5.64% 34.72% -13.98% -0.97% 6.90% 5.53%
Free Cash Flow Firm Q/Q Growth		 15.48% 70.48% 509.33% 20.01% 173.65% -101.05% -213.91% -501.73% -314.32% 39.64%
Invested Capital Q/Q Growth		 6.41% -6.00% -0.06% -1.67% -0.23% 6.46% -4.30% 2.13% 8.70% 0.60%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 44.75% -106.07% 73.79% 69.38% 27.95% 127.18% 8.22% 42.49% 149.63% 60.55%
Operating Margin		 33.52% -85.31% 70.03% 46.24% 28.24% 102.82% -12.99% 50.19% 130.17% 60.90%
EBIT Margin		 44.75% -106.07% 73.79% 69.38% 27.95% 127.18% 8.22% 42.49% 149.63% 60.55%
Profit (Net Income) Margin		 38.44% -107.83% 74.43% 65.28% 22.76% 120.39% -0.75% 36.18% 142.80% 56.32%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 85.90% 101.66% 100.86% 94.09% 81.44% 94.66% -9.15% 85.14% 95.43% 93.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 5.03% -9.24% 11.56% 7.68% 4.48% 16.53% -1.42% 7.82% 19.70% 8.91%
ROIC Less NNEP Spread (ROIC-NNEP)		 5.64% -15.20% 12.26% 10.18% 3.85% 18.69% -0.36% 6.18% 21.11% 8.39%
Return on Net Nonoperating Assets (RNNOA)		 2.49% -7.02% 5.29% 4.13% 1.79% 9.23% -0.17% 2.89% 10.75% 4.32%
Return on Equity (ROE)		 7.51% -16.27% 16.85% 11.81% 6.27% 25.76% -1.59% 10.71% 30.45% 13.23%
Cash Return on Invested Capital (CROIC)		 2.75% 3.77% 3.48% 4.79% 10.86% 5.91% 6.61% 2.95% -1.99% 1.70%
Operating Return on Assets (OROA)		 5.68% -13.82% 10.11% 9.40% 3.88% 18.04% 1.11% 5.47% 20.01% 7.92%
Return on Assets (ROA)		 4.88% -14.05% 10.19% 8.84% 3.16% 17.08% -0.10% 4.66% 19.09% 7.37%
Return on Common Equity (ROCE)		 4.31% -9.38% 9.90% 7.19% 3.85% 15.97% -1.00% 6.98% 19.96% 8.73%
Return on Equity Simple (ROE_SIMPLE)		 14.53% 0.00% 10.26% 7.50% 6.07% 0.00% 18.26% 15.90% 24.95% 0.00%
Net Operating Profit after Tax (NOPAT)		 192 -338 479 249 151 613 -52 270 735 362
NOPAT Margin		 33.52% -59.72% 70.03% 46.24% 28.24% 102.82% -9.09% 50.19% 130.17% 60.90%
Net Nonoperating Expense Percent (NNEP)		 -0.62% 5.96% -0.70% -2.50% 0.63% -2.16% -1.06% 1.65% -1.41% 0.52%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.03% - - - 3.78% - - - 2.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 8.84% 12.94% 12.53% 8.85% 10.67% 9.93% 10.15% 10.18% 10.04% 11.39%
R&D to Revenue		 4.45% 8.93% 0.07% 0.09% 9.42% 0.08% 0.09% 0.09% 0.09% 0.08%
Operating Expenses to Revenue		 66.48% 185.31% 29.97% 53.76% 71.76% -2.82% 112.99% 49.81% -30.17% 39.10%
Earnings before Interest and Taxes (EBIT)		 257 -600 505 373 150 758 47 228 845 359
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 257 -600 505 373 150 758 47 228 845 359
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.76 4.03 3.52 2.86 2.58 2.49 2.75 2.41 2.44 2.16
Price to Tangible Book Value (P/TBV)		 3.76 4.03 3.52 2.86 2.58 2.49 2.75 2.41 2.44 2.16
Price to Revenue (P/Rev)		 10.30 10.14 8.89 7.62 6.82 6.91 7.98 6.99 7.41 6.64
Price to Earnings (P/E)		 45.68 529.67 63.18 70.58 85.97 14.34 22.37 23.22 14.66 17.50
Dividend Yield		 1.94% 2.03% 2.23% 2.63% 3.00% 2.94% 2.71% 3.13% 2.93% 3.29%
Earnings Yield		 2.19% 0.19% 1.58% 1.42% 1.16% 6.97% 4.47% 4.31% 6.82% 5.72%
Enterprise Value to Invested Capital (EV/IC)		 2.11 2.19 2.05 1.83 1.69 1.65 1.79 1.62 1.62 1.50
Enterprise Value to Revenue (EV/Rev)		 14.35 14.01 12.43 10.90 10.22 10.47 11.47 10.60 11.38 10.59
Enterprise Value to EBITDA (EV/EBITDA)		 29.62 88.45 42.61 48.15 55.51 13.81 19.34 20.06 13.73 16.21
Enterprise Value to EBIT (EV/EBIT)		 29.94 89.89 42.61 48.15 55.51 13.81 19.34 20.06 13.73 16.21
Enterprise Value to NOPAT (EV/NOPAT)		 34.18 102.07 51.78 58.87 59.90 16.53 27.33 24.71 16.70 18.55
Enterprise Value to Operating Cash Flow (EV/OCF)		 15.62 14.62 10.79 9.36 8.53 8.25 9.81 8.89 9.21 8.66
Enterprise Value to Free Cash Flow (EV/FCFF)		 78.33 57.53 58.96 37.83 14.93 28.51 27.13 56.04 0.00 91.28
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.68 0.75 0.73 0.73 0.64 0.61 0.62 0.78 0.74 0.74
Long-Term Debt to Equity		 0.59 0.64 0.62 0.62 0.64 0.61 0.62 0.78 0.64 0.64
Financial Leverage		 0.44 0.46 0.43 0.41 0.47 0.49 0.46 0.47 0.51 0.52
Leverage Ratio		 1.70 1.74 1.73 1.72 1.68 1.69 1.69 1.78 1.71 1.69
Compound Leverage Factor		 1.46 1.76 1.74 1.62 1.37 1.60 -0.15 1.51 1.63 1.58
Debt to Total Capital		 40.57% 42.76% 42.03% 42.07% 39.01% 37.83% 38.36% 43.81% 42.58% 42.40%
Short-Term Debt to Total Capital		 5.69% 5.99% 5.89% 5.90% 0.00% 0.00% 0.00% 0.00% 5.58% 5.56%
Long-Term Debt to Total Capital		 34.89% 36.77% 36.14% 36.17% 39.01% 37.83% 38.36% 43.81% 37.00% 36.84%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 24.33% 23.42% 22.83% 20.85% 21.93% 21.94% 21.02% 18.88% 18.97% 18.91%
Common Equity to Total Capital		 35.10% 33.82% 35.14% 37.08% 39.06% 40.24% 40.62% 37.32% 38.45% 38.69%
Debt to EBITDA		 6.53 20.08 10.35 13.33 14.33 3.44 4.62 6.43 4.05 5.15
Net Debt to EBITDA		 4.43 13.42 6.53 7.89 10.42 2.70 3.35 4.07 2.98 3.75
Long-Term Debt to EBITDA		 5.62 17.27 8.90 11.46 14.33 3.44 4.62 6.43 3.52 4.47
Debt to NOPAT		 7.54 23.18 12.57 16.29 15.46 4.11 6.54 7.92 4.93 5.89
Net Debt to NOPAT		 5.11 15.49 7.93 9.65 11.24 3.23 4.73 5.02 3.63 4.30
Long-Term Debt to NOPAT		 6.48 19.93 10.81 14.01 15.46 4.11 6.54 7.92 4.28 5.12
Altman Z-Score		 2.37 2.15 2.26 2.00 2.00 2.14 2.18 1.70 1.83 1.59
Noncontrolling Interest Sharing Ratio		 42.58% 42.32% 41.24% 39.13% 38.55% 38.02% 36.74% 34.79% 34.44% 34.04%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.07 2.19 2.36 2.52 13.51 7.90 12.52 9.35 1.54 1.44
Quick Ratio		 1.96 2.08 2.32 2.48 13.16 7.65 12.30 9.26 1.51 1.41
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -339 -100 410 492 1,346 -14 -44 -267 -1,107 -668
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -7.22 -2.13 8.73 10.48 29.25 -0.30 -1.00 -5.45 -16.65 -10.16
Operating Cash Flow to Interest Expense		 11.47 12.14 22.02 12.95 12.46 16.35 15.03 13.43 10.58 11.29
Operating Cash Flow Less CapEx to Interest Expense		 11.47 12.14 22.02 12.95 12.46 16.35 15.03 13.43 10.58 11.29
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.14 0.14 0.14 0.14 0.13 0.13 0.13 0.13
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 15,250 14,336 14,327 14,088 14,055 14,963 14,320 14,625 15,897 15,993
Invested Capital Turnover		 0.15 0.15 0.17 0.17 0.16 0.16 0.16 0.16 0.15 0.15
Increase / (Decrease) in Invested Capital		 532 -238 69 -243 -1,195 627 -7.24 537 1,842 1,030
Enterprise Value (EV)		 32,238 31,341 29,325 25,746 23,758 24,661 25,678 23,726 25,778 23,978
Market Capitalization		 23,153 22,687 20,965 17,994 15,854 16,276 17,871 15,634 16,789 15,030
Book Value per Share		 $10.13 $9.27 $9.80 $10.35 $10.20 $10.92 $14.49 $10.84 $11.58 $11.79
Tangible Book Value per Share		 $10.13 $9.27 $9.80 $10.35 $10.20 $10.92 $14.49 $10.84 $11.58 $11.79
Total Capital		 17,528 16,642 16,943 16,940 15,716 16,220 16,003 17,354 17,866 17,955
Total Debt		 7,111 7,116 7,121 7,126 6,131 6,135 6,139 7,602 7,607 7,612
Total Long-Term Debt		 6,115 6,119 6,123 6,127 6,131 6,135 6,139 7,602 6,610 6,615
Net Debt		 4,821 4,756 4,492 4,220 4,458 4,827 4,443 4,817 5,601 5,552
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 666 649 535 603 659 618 563 500 625 559
Debt-free Net Working Capital (DFNWC)		 2,207 2,386 2,513 2,781 1,601 1,113 1,435 2,303 1,623 1,546
Net Working Capital (NWC)		 1,210 1,388 1,514 1,781 1,601 1,113 1,435 2,303 626 549
Net Nonoperating Expense (NNE)		 -28 272 -30 -102 29 -105 -47 75 -71 27
Net Nonoperating Obligations (NNO)		 4,834 4,811 4,505 4,274 4,470 4,879 4,456 4,873 5,639 5,650
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 29.65% 29.02% 22.66% 25.52% 28.35% 26.23% 25.16% 22.36% 27.57% 24.70%
Debt-free Net Working Capital to Revenue		 98.22% 106.63% 106.51% 117.76% 68.87% 47.26% 64.11% 102.94% 71.64% 68.31%
Net Working Capital to Revenue		 53.87% 62.05% 64.19% 75.44% 68.87% 47.26% 64.11% 102.94% 27.65% 24.23%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.32 ($1.04) $0.76 $0.51 $0.16 $1.11 $0.01 $0.23 $1.22 $0.46
Adjusted Weighted Average Basic Shares Outstanding		 439.29M 437.96M 445.61M 450.41M 448.44M 447.60M 448.62M 451.02M 447.63M 448.19M
Adjusted Diluted Earnings per Share		 $0.32 ($1.04) $0.76 $0.50 $0.16 $1.11 $0.01 $0.23 $1.21 $0.46
Adjusted Weighted Average Diluted Shares Outstanding		 607.23M 437.97M 607.25M 605.86M 601.14M 602.90M 597.48M 596.91M 592.73M 594.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 607.22M 607.22M 607.14M 601.82M 597.43M 597.43M 597.44M 593.46M 589.18M 576.45M
Normalized Net Operating Profit after Tax (NOPAT)		 135 -338 335 174 106 429 -52 189 515 253
Normalized NOPAT Margin		 23.46% -59.72% 49.02% 32.36% 19.77% 71.98% -9.09% 35.13% 91.12% 42.63%
Pre Tax Income Margin		 38.44% -107.83% 74.43% 65.28% 22.76% 120.39% -0.75% 36.18% 142.80% 56.32%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 5.46 -12.78 10.75 7.95 3.26 16.04 1.06 4.66 12.70 5.47
NOPAT to Interest Expense		 4.09 -7.20 10.20 5.30 3.29 12.97 -1.17 5.50 11.05 5.50
EBIT Less CapEx to Interest Expense		 5.46 -12.78 10.75 7.95 3.26 16.04 1.06 4.66 12.70 5.47
NOPAT Less CapEx to Interest Expense		 4.09 -7.20 10.20 5.30 3.29 12.97 -1.17 5.50 11.05 5.50
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 101.71% 413.23% 154.07% 157.32% 169.03% 50.28% 71.99% 83.82% 50.60% 64.92%
Augmented Payout Ratio		 101.71% 413.23% 154.07% 185.87% 242.74% 68.21% 71.99% 108.13% 62.69% 82.17%

Frequently Asked Questions About Royalty Pharma's Financials

When does Royalty Pharma's financial year end?

According to the most recent income statement we have on file, Royalty Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Royalty Pharma's net income changed over the last 6 years?

Royalty Pharma's net income appears to be on a downward trend, with a most recent value of $1.33 billion in 2024, falling from $1.52 billion in 2018. The previous period was $1.70 billion in 2023.

What is Royalty Pharma's operating income?
Royalty Pharma's total operating income in 2024 was $1.29 billion, based on the following breakdown:
  • Total Gross Profit: $2.26 billion
  • Total Operating Expenses: $971.13 million
How has Royalty Pharma revenue changed over the last 6 years?

Over the last 6 years, Royalty Pharma's total revenue changed from $1.79 billion in 2018 to $2.26 billion in 2024, a change of 26.1%.

How much debt does Royalty Pharma have?

Royalty Pharma's total liabilities were at $7.88 billion at the end of 2024, a 25.1% increase from 2023, and a 24.9% increase since 2019.

How much cash does Royalty Pharma have?

In the past 5 years, Royalty Pharma's cash and equivalents has ranged from $246.20 million in 2019 to $1.71 billion in 2022, and is currently $929.03 million as of their latest financial filing in 2024.

How has Royalty Pharma's book value per share changed over the last 6 years?

Over the last 6 years, Royalty Pharma's book value per share changed from 0.00 in 2018 to 11.79 in 2024, a change of 1,179.0%.

Remove Ads

Related Companies

This page (NASDAQ:RPRX) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Is it CRAZY to still want reliable profits, despite this market?
Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...
Brownstone Research | Sponsored
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
Tariffs. Volatility. Fear. Here’s the Plan.
Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...
Investors Alley | Sponsored
This story is about to go viral
This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...
Stansberry Research | Sponsored
How War with China Could Start in 128 Days
The clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...
Behind the Markets | Sponsored